LONDON, ONTARIO--(Marketwire - December 10, 2008) - Stellar Pharmaceuticals Inc. ("Stellar") (OTCBB: SLXCF), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today reported signing a licensing agreement for the distribution and sale of Uracyst® in Denmark, Finland, Iceland, Norway and Sweden, with Vitaflo Scandinavia AB ("Vitaflo"), a specialty pharmaceutical sales and marketing company, which is a subsidiary of Navamedic ASA. Based in Gothenburg, Sweden, Vitaflo promotes branded and generic prescription medicines, food for specific medical needs, as well as, OTC products in Denmark, Finland, Iceland, Norway and Sweden. One of Vitaflo's major focus areas is women's health. Uracyst® is Stellar's proprietary urology product used in the treatment of interstitial cystitis and painful bladder syndrome. Ninety percent of IC patients are women. They range in age from teens up to their eighties.
